Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 24.69B |
| Revenue (ttm) | 48.25B |
| Net Income (ttm) | -2.64B |
| Shares Out | n/a |
| EPS (ttm) | -2.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,700 |
| Average Volume | 4,620 |
| Open | 24.71 |
| Previous Close | 24.48 |
| Day's Range | 24.64 - 24.71 |
| 52-Week Range | 19.50 - 34.01 |
| Beta | 1.01 |
| RSI | 57.77 |
| Earnings Date | May 13, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
World Bank adds Bayer, Hyatt and other CEOs to private sector initiative
The World Bank on Wednesday added four top executives, including Bayer AG CEO Bill Anderson and Hyatt Hotels CEO Mark Hoplamazian, to an initiative working to address barriers to private sector invest...
ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ -- powered by Guardant Health liquid biopsy genomic data -- and AI Sa...
ConcertAI Announce Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ -- powered by Guardant Health liquid biopsy genomic data -- and AI Sa...
CEO do Bayer revela 'acordo de cavalheiros' para liberar Xabi, alvo do Real
CEO do Bayer revela 'acordo de cavalheiros' para liberar Xabi Alonso, alvo do Real
Bayer CEO: targeting US state regulation to stem glyphosate costs
Bayer is lobbying U.S. states to adjust their regulatory framework in its battle to wind down costly litigation over its weedkiller glyphosate, the German chemicals company's CEO said in a draft speec...
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
MYERSTOWN, Pa.--(BUSINESS WIRE)--Today, Bayer proudly celebrated the grand opening of its new 70,000 square foot expansion at its Myerstown facility, following a $44 million investment in 2022. This s...
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting.
Bayer is said to consider ending production of Roundup amid legal costs
Farmers' Favorite Weedkiller Nears Its End, Bayer Warns
The German company cites mounting costs from lawsuits blaming Roundup for causing cancer.
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. (...
FDA Grants Complete Approval To Bayer's Drug For Certain Type Cancer With Mutation
The U.S. Food And Drug Administration (FDA) granted full approval to Bayer AG’s (OTC: BAYRY) Vitrakvi (larotrectinib) for adult and pediatric patients with solid tumors that have a neurotrophic recep...
Bayer petitions U.S. Supreme Court to review Roundup case
Bayer renews bid for US Supreme Court to curb glyphosate cases
Bayer said on Friday it was again petitioning the U.S. Supreme Court to sharply limit legal claims that its Roundup weedkiller causes cancer, seeking to avoid potentially billions of dollars in damage...
Bayer announces filing of petition to U.S. Supreme Court for review of Durnell Roundup™ case
LEVERKUSEN, Germany--(BUSINESS WIRE)--Today Bayer – through its indirect subsidiary Monsanto – filed its petition for a writ of certiorari with the U.S. Supreme Court in the Durnell case, just three b...
Zone Agtech, Bayer and Axceta Sign Agreement to Build Innovation Consortium in AgriTech and Greenhouse Technology
L'ASSOMPTION RCM, QC , April 3, 2025 /CNW/ - Bayer's Crop Science division, Zone Agtech, and Axceta have officially signed a Memorandum of Understanding (MOU) to launch a three-party collaboration aim...
Bayer exec urges EU to avoid trade war as pharma dodges tariffs (for now)
Bayer’s head of Pharmaceuticals talks to Euractiv about US tariffs, expresses scepticism over CMA, and how the discussion on RDP should be focused on increasing it for incentivising competitiveness.
Bayer eyes launch of menopause relief, heart drugs this year
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business ...
Elliott held talks with private equity as it considered new Bayer campaign
US hedge fund gauged investor interest in German conglomerate’s consumer health business
Bayer in licenses Puhe BioPharma’s cancer candidate
Bayer acquires rights in Puhe BioPharma cancer drug candidate
Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe BioPharma.
ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American Coll...
Bayer told to pay almost $2.1bn over Roundup cancer link claim
A jury in the US state of Georgia has ordered Monsanto parent Bayer to pay nearly $2.1bn (1.94bn) in damages to a man who says the companys Roundup weed killer caused his cancer, according to attorney...
Monsanto parent ordered to pay $2B in Roundup lawsuit damages
The company behind Roundup weedkiller herbicide was ordered to pay more than $2 billion in a man’s cancer lawsuit. According to his attorneys, John Barnes developed non-Hodgkin’s lymphoma after using ...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2188635534-2cd8b4b5697e42f58f858d2c64bafe8f.jpg)
Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case
Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer.
Push-pull over glyphosate in Germany
Bayer is confident it can "restore" the authorisation of the controversial weedkiller.